What is Staphylococcus lugdunensis and how should it be treated when isolated from a sterile site?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 8, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Staphylococcus lugdunensis: A Highly Virulent Coagulase-Negative Staphylococcus Requiring Aggressive Treatment

Staphylococcus lugdunensis is a coagulase-negative staphylococcus that behaves like Staphylococcus aureus and must be treated with β-lactam antibiotics (oxacillin or cefazolin) when isolated from sterile sites, not with the typical empiric vancomycin used for other coagulase-negative staphylococci. 1, 2

What Makes S. lugdunensis Different

S. lugdunensis is fundamentally distinct from other coagulase-negative staphylococci in three critical ways:

  • Virulence comparable to S. aureus: Causes aggressive infective endocarditis with high rates of valve destruction, perivalvular abscess formation, and metastatic infection 1, 2
  • Antibiotic susceptibility profile: Remains highly susceptible to most antibiotics, with 84-86% susceptibility to oxacillin 3, 4, 5
  • Clinical outcomes: Mortality rates and complications mirror S. aureus rather than typical coagulase-negative staphylococci 6

Critical Diagnostic Considerations

Species-level identification is mandatory - do not accept "coagulase-negative staphylococcus" as a final result when isolated from sterile sites. Modern laboratories using MALDI-TOF mass spectrometry can reliably identify S. lugdunensis 6. Initial screening uses pyrrolidonyl aminopeptidase hydrolysis testing 2.

Treatment Algorithm by Infection Site

Infective Endocarditis (Most Critical)

S. lugdunensis endocarditis requires the same aggressive approach as S. aureus endocarditis:

  • First-line therapy: Oxacillin or cloxacillin (if methicillin-susceptible) for 4-6 weeks 1
  • Penicillin allergy: Attempt penicillin desensitization in stable patients; vancomycin is inferior to β-lactams 1
  • Alternative if β-lactams contraindicated: High-dose daptomycin combined with another antistaphylococcal agent 1
  • Monitor intensively for perivalvular extension and metastatic infection (occurs frequently) 2, 7, 2
  • Surgical consultation early: High rates of valve destruction necessitate frequent surgical intervention 1, 8

Bacteremia from Sterile Sites

  • Oxacillin 2g IV every 4-6 hours (if methicillin-susceptible) 9, 4
  • Cefazolin 2g IV three times daily is an acceptable alternative, particularly for outpatient parenteral therapy 9
  • Duration: Minimum 2 weeks for uncomplicated bacteremia; 4-6 weeks if complicated by metastatic foci 9
  • Mandatory workup: Echocardiography (preferably TEE), repeat blood cultures, imaging for metastatic infection 9, 8

Prosthetic Joint Infections

β-lactam therapy demonstrates superior outcomes compared to vancomycin:

  • Oxacillin-based regimen: Median 38 days parenteral therapy showed 92% treatment success at 2 years 4
  • Vancomycin: Only 76% success rate at 2 years (statistically inferior, P=0.015) 4
  • Recommendation: Use parenteral β-lactam (oxacillin or cefazolin) for prosthetic joint infections 4

Skin and Soft Tissue Infections

  • Most common presentation (63% of infections) 5
  • Treatment: Oxacillin or cefazolin based on susceptibility 3, 6
  • Important: >50% require procedural intervention (incision and drainage, debridement) for cure 5
  • Duration: 7-14 days depending on severity 6

Antimicrobial Resistance Patterns

S. lugdunensis maintains excellent susceptibility profiles:

  • Oxacillin: 84-86% susceptible 3, 4, 5
  • Vancomycin: 100% susceptible 10, 3, 5
  • Trimethoprim-sulfamethoxazole: 95-99% susceptible 10, 3, 5
  • Tetracyclines: 95% susceptible 5
  • Penicillin: 15-87% resistance (wide geographic variation) 3

Methicillin resistance is rare but increasing:

  • mecA gene carriage documented in 2-16% of isolates 10, 3, 11
  • SCCmec type V most common (66%), followed by type II (19%) 10
  • All mecA-positive isolates remain susceptible to vancomycin and teicoplanin 10

Common Pitfalls to Avoid

  1. Do not treat as typical coagulase-negative staphylococcus: Empiric vancomycin while awaiting susceptibilities is acceptable, but switch to β-lactam therapy once susceptibilities confirm oxacillin susceptibility 4

  2. Do not dismiss as contaminant: Unlike S. epidermidis, S. lugdunensis from blood cultures is rarely a contaminant and warrants full evaluation 9, 6

  3. Do not use short-course therapy for endocarditis: Despite being coagulase-negative, this organism requires full 4-6 week courses 1

  4. Do not overlook urogenital sources: 32% of prosthetic joint infections had underlying urogenital abnormalities as the source 4

  5. Do not rely on vancomycin when β-lactams are available: Clinical outcomes are demonstrably worse with vancomycin therapy 4

Special Populations

Hemodialysis patients: Arteriovenous fistulas are potential sources even without localized signs of infection; buttonhole cannulation method increases risk 9

Prosthetic devices: High affinity for foreign bodies including cardiac devices, prosthetic valves, and joint prostheses 6, 4

Optimal Antibiotic Selection Hierarchy

For oxacillin-susceptible isolates:

  1. Penicillin G (MIC 3-fold lower than oxacillin; may be optimal choice) 3
  2. Oxacillin/cloxacillin (standard therapy) 1, 4
  3. Cefazolin (convenient for outpatient therapy) 9

For oxacillin-resistant isolates:

  1. Vancomycin (100% susceptible) 10, 3
  2. Teicoplanin (100% susceptible) 10
  3. Trimethoprim-sulfamethoxazole (98.6% susceptible, oral option) 10

References

Research

Staphylococcus lugdunensis: antimicrobial susceptibility and optimal treatment options.

European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2019

Research

High-Grade Staphylococcus lugdunensis Bacteremia in a Patient on Home Hemodialysis.

Federal practitioner : for the health care professionals of the VA, DoD, and PHS, 2023

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.